Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Infectious Agents in Atherosclerotic Cardiovascular Diseases through Oxidative Stress.

Di Pietro M, Filardo S, Falasca F, Turriziani O, Sessa R.

Int J Mol Sci. 2017 Nov 18;18(11). pii: E2459. doi: 10.3390/ijms18112459. Review.

2.

Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns.

Falasca F, Di Carlo D, De Vito C, Bon I, d'Ettorre G, Fantauzzi A, Mezzaroma I, Fimiani C, Re MC, Vullo V, Antonelli G, Turriziani O.

BMC Infect Dis. 2017 Aug 22;17(1):581. doi: 10.1186/s12879-017-2676-2.

3.

Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors.

Mazzuti L, Mezzaroma I, Falasca F, Turriziani O.

AIDS. 2017 Aug 24;31(13):1900-1901. doi: 10.1097/QAD.0000000000001581. No abstract available.

PMID:
28746089
4.

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.

Andreis S, Basso M, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, Rossi MC, Francavilla E, Boldrin C, Alvarez M, Dal Bello F, Mengoli C, Turriziani O, Sarmati L, Antonelli G, Andreoni M, Palù G, Parisi SG.

J Glob Antimicrob Resist. 2017 Sep;10:106-112. doi: 10.1016/j.jgar.2017.05.011. Epub 2017 Jul 18.

PMID:
28732792
5.

Consolidation of molecular testing in clinical virology.

Scagnolari C, Turriziani O, Monteleone K, Pierangeli A, Antonelli G.

Expert Rev Anti Infect Ther. 2017 Apr;15(4):387-400. doi: 10.1080/14787210.2017.1271711. Epub 2016 Dec 24. Review.

PMID:
28002969
6.

Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1.

Montagna C, Mazzuti L, Falasca F, Maida P, Bucci M, D'Ettorre G, Mezzaroma I, Fantauzzi A, Alvaro N, Vullo V, Antonelli G, Turriziani O.

J Glob Antimicrob Resist. 2015 Dec;3(4):267-272. doi: 10.1016/j.jgar.2015.07.006. Epub 2015 Aug 22.

PMID:
27842871
7.

Lack of association of Chlamydia pneumoniae with cardiovascular diseases in virologically suppressed HIV patients.

Sessa R, Di Pietro M, Filardo S, Bressan A, Mazzuti L, Serafino S, Fantauzzi A, Turriziani O.

New Microbiol. 2017 Jan;40(1):33-37. Epub 2016 Nov 7.

8.

Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment.

Massimi I, Lotti LV, Temperilli F, Mancone M, Sardella G, Calcagno S, Turriziani O, Frati L, Pulcinelli FM.

Thromb Haemost. 2016 Nov 30;116(6):1100-1110. Epub 2016 Sep 29.

PMID:
27683757
9.

IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection.

Monteleone K, Scheri GC, Statzu M, Selvaggi C, Falasca F, Giustini N, Mezzaroma I, Turriziani O, d'Ettorre G, Antonelli G, Scagnolari C.

Arch Virol. 2016 Nov;161(11):3263-8. doi: 10.1007/s00705-016-3016-3. Epub 2016 Aug 24.

PMID:
27558125
10.

Evaluation of performances of VERSANT HCV RNA 1.0 assay (kPCR) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 at low level viremia.

Mazzuti L, Lozzi MA, Riva E, Maida P, Falasca F, Antonelli G, Turriziani O.

New Microbiol. 2016 Jul;39(3):224-227. Epub 2016 Jun 10.

11.

First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing.

Meini G, Dello Russo C, Allice T, Barresi R, D'Arrigo R, Falasca F, Lipsi MR, Paolucci S, Zanussi S, Antonetti R, Baldanti F, Basaglia G, Bruzzone B, Polilli E, Ghisetti V, Pucillo LP, Turriziani O, Pirazzoli A, Navarra P, Zazzi M.

J Clin Virol. 2016 May;78:1-3. doi: 10.1016/j.jcv.2016.02.020. Epub 2016 Feb 23.

PMID:
26946153
12.

Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients.

Vicenti I, Falasca F, Sticchi L, Bruzzone B, Turriziani O, Zazzi M.

J Clin Virol. 2016 Mar;76:20-3. doi: 10.1016/j.jcv.2016.01.006. Epub 2016 Jan 12.

PMID:
26802683
13.

Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.

d'Ettorre G, Ceccarelli G, Serafino S, Giustini N, Cavallari EN, Bianchi L, Pavone P, Bellelli V, Turriziani O, Antonelli G, Stroffolini T, Vullo V.

J Med Virol. 2016 Aug;88(8):1347-56. doi: 10.1002/jmv.24475. Epub 2016 Jan 20.

PMID:
26765625
14.

Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients.

Falasca F, Dello Russo C, Mora B, Pirazzoli A, Fantauzzi A, Navarra P, Pizzuti A, De Vito C, Antonelli G, Turriziani O.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):654-7. doi: 10.1089/AID.2015.0303. Epub 2016 Feb 10.

15.

ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response.

Scagnolari C, Monteleone K, Selvaggi C, Pierangeli A, D'Ettorre G, Mezzaroma I, Turriziani O, Gentile M, Vullo V, Antonelli G.

Immunobiology. 2016 Feb;221(2):282-90. doi: 10.1016/j.imbio.2015.10.007. Epub 2015 Oct 30.

PMID:
26563749
16.

An epidemiological investigation to reconstruct a probable human immunodeficiency virus-1 transmission network: a case report.

Serafino S, Cella E, Montagna C, Cavallari EN, Vittozzi P, Lo Presti A, Giovanetti M, Mazzuti L, Turriziani O, Ceccarelli G, d'Ettorre G, Vullo V, Ciccozzi M.

J Med Case Rep. 2015 Nov 3;9:253. doi: 10.1186/s13256-015-0717-2.

17.

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization.

Fantauzzi A, Floridia M, Falasca F, Spanedda P, Turriziani O, Vullo V, Mezzaroma I.

New Microbiol. 2015 Oct;38(4):531-40. Epub 2015 Oct 20.

18.

Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial.

d'Ettorre G, Ceccarelli G, Giustini N, Serafino S, Calantone N, De Girolamo G, Bianchi L, Bellelli V, Ascoli-Bartoli T, Marcellini S, Turriziani O, Brenchley JM, Vullo V.

PLoS One. 2015 Sep 16;10(9):e0137200. doi: 10.1371/journal.pone.0137200. eCollection 2015.

19.

MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients.

Monteleone K, Selvaggi C, Cacciotti G, Falasca F, Mezzaroma I, D'Ettorre G, Turriziani O, Vullo V, Antonelli G, Scagnolari C.

BMC Infect Dis. 2015 Feb 12;15:51. doi: 10.1186/s12879-015-0768-4.

20.

Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen.

Falasca F, Mazzuti L, DʼEttorre G, Paoletti F, Tripolino O, Serafino S, Antonelli G, Turriziani O.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):e18-20. doi: 10.1097/QAI.0000000000000414. No abstract available.

PMID:
25590274

Supplemental Content

Loading ...
Support Center